News & Insights

Physician-led coverage of peptides, TRT, and FDA regulation.

We track the studies, advisory committee votes, and regulatory filings that actually change how testosterone and peptide therapy are prescribed — and translate them without the hype or the panic.

FDA & Regulation

FDA advisory committee recommends 6 of 7 peptides for 503A compounding list — what it means for patients

On July 23–24, the FDA's Pharmacy Compounding Advisory Committee voted to recommend BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax for inclusion on the 503A Bulks List. Here's what the vote does — and what it doesn't — for patients considering peptide therapy.

Aurafil Health Medical Team Jul 25, 2026 8 min read

TRT Studies

Retatrutide clears Phase 3: 22.6% weight loss and a Q1 2027 FDA submission

What the TRIUMPH-2 and TRIUMPH-3 data show — and why it matters for men on TRT.

Medical Team Jul 24, 2026 6 min read

TRT Studies

One year after TRAVERSE: what the trial changed in TRT prescribing

What the 5,246-patient RCT concluded, what caveats remain, and how it changed real prescribing.

Medical Team Jul 21, 2026 10 min read

Physician-led coverage of peptides, TRT, and FDA regulation.

FDA advisory committee recommends 6 of 7 peptides for 503A compounding list — what it means for patients

Retatrutide clears Phase 3: 22.6% weight loss and a Q1 2027 FDA submission

One year after TRAVERSE: what the trial changed in TRT prescribing

Get physician-reviewed updates on peptides, FDA rulings, and TRT research.